Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$6.27B
sum of reported positions
Reported positions
833
Changes vs prior quarter
994
141 new · 267 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 299 measured positions in 6 quarters, the typical new or larger position finished −3.3 pts against the S&P 500 and 39% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
| 1.05M | $146M | 2.3% | |
| 333K | $83.8M | 1.3% | |
| 223K | $76.6M | 1.2% | |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $6.73B | $6.27B |
| Positions | 959 | 833 |
| Biggest line | — | Intel 2% |
| 957K |
| $74.9M |
| 1.2% |
| 403K | $73M | 1.2% |
| 696K | $71.2M | 1.1% |
| 76K | $70.7M | 1.1% |
| 176K | $69.9M | 1.1% |
| 514K | $69.6M | 1.1% |
| 922K | $68.6M | 1.1% |
| 1.66M | $68.6M | 1.1% |
| 65K | $68.2M | 1.1% |
| 396K | $66.5M | 1.1% |
| 680K | $65.3M | 1.0% |
| 236K | $65.1M | 1.0% |
| 409K | $62M | 1.0% |
| 660K | $60.5M | 1.0% |
| 571K | $59.1M | 0.9% |
| 151K | $54.8M | 0.9% |
| 849K | $54.5M | 0.9% |
| 185K | $54.3M | 0.9% |
| 1.57M | $50.2M | 0.8% |
| 642K | $49.9M | 0.8% |
| 176K | $49.9M | 0.8% |
| 268K | $48.2M | 0.8% |
Ingevity, Corp. (NGVT)
19K → 25K shares (+33%)
Olema Pharmaceuticals (OLMA)
114K → 148K shares (+30%)
Iradimed (IRMD)
2,680 → 19K shares (+620%)
United States Lime & Minerals, Inc. (USLM)
6,564 → 18K shares (+167%)
National Healthcare, Corp. (NHC)
8,346 → 8,635 shares (+4%)
Bumble (BMBL)
104K → 559K shares (+436%)
National Beverage Corp. (FIZZ)
24K → 57K shares (+135%)
Smartstop Self Storage REIT (SMA)
30K → 54K shares (+81%)
Bw Lpg (BWLP)
33K → 100K shares (+203%)
Ginkgo Bioworks Holdings (DNA)
127K → 176K shares (+39%)
Build-A-Bear Workshop (BBW)
31K → 57K shares (+84%)
Minerals Technologies (MTX)
14K → 23K shares (+71%)
Rapport Therapeutics (RAPP)
23K → 40K shares (+76%)
Personalis (PSNL)
61K → 121K shares (+98%)
Immunome (IMNM)
44K → 74K shares (+68%)
C4 Therapeutics (CCCC)
260K → 335K shares (+29%)
Editas Medicine (EDIT)
333K → 477K shares (+43%)
CVR Energy, Inc. (CVI)
37K → 56K shares (+50%)
Sensient Technologies (SXT)
4,234 → 12K shares (+190%)
Tootsie Roll Industries, Inc. (TR)
12K → 38K shares (+205%)
G-III Apparel Group, Ltd. (GIII)
28K → 44K shares (+58%)
Rezolute (RZLT)
114K → 280K shares (+145%)
Collegium Pharmaceutical, Inc. (COLL)
6,210 → 39K shares (+533%)
4d Molecular Therapeutics (FDMT)
28K → 107K shares (+275%)
Clear Channel Outdoor Holdings (CCO)
330K → 586K shares (+78%)
